Trade-Ideas LLC identified

Chimerix

(

CMRX

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Chimerix as such a stock due to the following factors:

  • CMRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $34.2 million.
  • CMRX has traded 1.2 million shares today.
  • CMRX is trading at 10.96 times the normal volume for the stock at this time of day.
  • CMRX is trading at a new high 5.02% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CMRX with the Ticky from Trade-Ideas. See the FREE profile for CMRX NOW at Trade-Ideas

More details on CMRX:

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. Currently there are 6 analysts that rate Chimerix a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for Chimerix has been 774,900 shares per day over the past 30 days. Chimerix has a market cap of $305.5 million and is part of the health care sector and drugs industry. The stock has a beta of -0.18 and a short float of 8.6% with 0.61 days to cover. Shares are down 81.7% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Chimerix as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:

  • CHIMERIX INC's earnings per share declined by 48.9% in the most recent quarter compared to the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, CHIMERIX INC reported poor results of -$1.77 versus -$1.45 in the prior year. For the next year, the market is expecting a contraction of 46.3% in earnings (-$2.59 versus -$1.77).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 91.4% when compared to the same quarter one year ago, falling from -$16.95 million to -$32.45 million.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Biotechnology industry and the overall market, CHIMERIX INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$24.93 million or 117.74% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 82.92%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 48.93% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.